A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).

Oligodendrogliomas in the novel edition of the Central Nervous System (CNS) World Health Organization (WHO) classification are now molecularly defined by isocitrate dehydrogenase (IDH)1 or IDH2 mutations and 1p/19q co-deletion. The prognosis of these molecularly defined tumors is to be determined in new series since survival data from older histology-based studies and population-based registries are confounded by the inclusion of 20-70% not molecularly matching subsets. Also, the optimal treatment is a matter of ongoing investigations. An extensive, but safe surgery is associated with improved

Trial Details

NCT ID
NCT05331521
Phase
PHASE3
Sponsor
University Hospital Heidelberg
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • CETEG
  • PCV
  • RT
Locations (sample)
  • Heidelberg, Baden-Wurttemberg, Germany|49.40768,8.69079
  • Berlin, Germany|52.52437,13.41053
  • Bochum, Germany|51.48165,7.21648
  • Bonn, Germany|50.73438,7.09549
  • Chemnitz, Germany|50.8357,12.92922

Key Eligibility Criteria

  • Histologically confirmed, newly diagnosed CNS WHO grade 2 or 3 glioma.
  • Tumor carries an isocitrate dehydrogenase (IDH) mutation (determined by immunohistochemistry (IHC) and/or deoxyribonucleic acid (DNA) sequencing).
  • Tumor is co-deleted for 1p/19q (determined by copy number variations, fluorescence in situ hybridization (FISH), multiplex ligation-dependent probe…
  • Biopsy (with sufficient tissue for molecular pathology) or resection.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →